Harbour Investments Inc. Has $485,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Harbour Investments Inc. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 461 shares of the biopharmaceutical company’s stock after selling 92 shares during the quarter. Harbour Investments Inc.’s holdings in Regeneron Pharmaceuticals were worth $485,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. SteelPeak Wealth LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares during the period. Atria Investments Inc grew its position in Regeneron Pharmaceuticals by 12.2% in the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after acquiring an additional 941 shares in the last quarter. Nordea Investment Management AB grew its position in Regeneron Pharmaceuticals by 23.2% in the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after acquiring an additional 5,495 shares in the last quarter. Tidal Investments LLC grew its position in Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after acquiring an additional 711 shares in the last quarter. Finally, Sierra Summit Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $1,011,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on REGN. Argus boosted their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. Royal Bank of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $1,232.00 to $1,240.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler boosted their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Finally, Cantor Fitzgerald boosted their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,108.45.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $1,199.29 on Thursday. The stock has a market cap of $132.14 billion, a P/E ratio of 35.43, a PEG ratio of 3.12 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The company has a fifty day moving average price of $1,094.40 and a 200 day moving average price of $1,008.03. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the company earned $8.79 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the sale, the executive vice president now owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the sale, the executive vice president now owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,397,202. The disclosure for this sale can be found here. Insiders sold a total of 16,559 shares of company stock worth $17,087,606 in the last ninety days. 7.48% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.